Aim Convalescent plasma proved to increase survival rates in other severe viral infections.
Therefore, convalescent plasma could be a promising treatment option for severe COVID-19 …

Abstract Objectives and background In December 2019, the first case of COVID-19 was
reported in Wuhan, China. Its causative virus, is a novel strain of RNA viruses with high …

Background COVID-19 is highly contagious, potentially deadly current pandemic with no
evidence-based cure or vaccines. The efficacy and safety of transfusion plasma of recovered …

The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has
spread rapidly around the world in the last year causing the coronavirus disease 2019 …

Key Points A severely immunocompromised patient with MM and COVID19 who received a
convalescent plasma product showed SARS-CoV-2 clearance. The convalescent plasma …

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has infected approximately
6.5 million people, with a loss of over 383,000 lives across the globe (as of 03 June 2020) …

There have been several efforts to minimize the effects caused by the COVID-19 virus
around the world. Vaccines were developed in record time and alternative therapies were …

The COVID-19 pandemic has affected 187 countries, representing a global public health
problem. The increasing number of critically ill patients and deaths have fueled a desperate …

Editorial The transfer of immunity from a protected to an infected host dates back to the end
of the XIXth century, on both experimental and clinical grounds. Perhaps the pioneer large …

Background Although many trials are currently investigating the safety and efficacy of
convalescent plasma (CP) in critically ill COVID‐19 patients, there is a paucity of ongoing …